Antipsychotic Use: Cross-Sectional Opinion Survey of Psychiatrists in India and United Kingdom

Zina Sherzad Qadir, Nilamadhab Kar, Patrick Ball, Hana Morrissey

Research output: Contribution to journalArticlepeer-review

Abstract

The aim of this survey of psychiatrists from the UK and India was to compare their opinions on antipsychotic medication choice and their experiences of such medications’ effectiveness and tolerability in patients who were newly diagnosed with acute schizophrenia. Following ethical approval, a cross-sectional online survey of psychiatrists from the UK and India was conducted. Ninety-five responses were received from each country. The most selected first-line APDs in both countries were olanzapine (47.5%), risperidone (42.8%) and aripiprazole (25.3%). A total of 60% of psychiatrists from India (60%) and 48% from the UK (48%) selected ‘medication efficacy’ as the main factor in their choice. Reassessment and consideration to switch most often took place within 4–6 weeks (53.7%) and 3–6 months (11.6%). The major reasons for switching antipsychotic medications were poor clinical efficacy (69%) and lack of tolerability (45%). Nonadherence was the most common reason for relapse (90% of UK psychiatrists and 70% of Indian psychiatrists), followed by illicit drug use (27.6%). The most commonly reported side effects that led to nonadherence were weight gain (10.8%), drowsiness (10.4%), erectile dysfunction and movement disorders (equally 8.7%). It was concluded that olanzapine, risperidone and aripiprazole are the most commonly selected as the initial treatment choice by psychiatrists from India and the UK. They are perceived as widely effective and well tolerated.
Original languageEnglish
Number of pages13
JournalPharmacy Practice and Practice-Based Research
Volume11
Issue number5
DOIs
Publication statusPublished - 09 Oct 2023

Fingerprint

Dive into the research topics of 'Antipsychotic Use: Cross-Sectional Opinion Survey of Psychiatrists in India and United Kingdom'. Together they form a unique fingerprint.

Cite this